In vivo tumouricidal effect of T lymphocytes activated by liposomes containing adriamycin on chemically-induced rat malignant fibrous histiocytoma

Anticancer Research

Volumn 17, Issue 6 D, 1997, Pages 4347-4354

  Yakushiji, Toshitake ^a   Yonemura, Kensuke ^a   Nishida, Kimiaki ^a   Takagi, Katsumasa ^a  

^a KUMAMOTO UNIVERSITY   (Japan)

Author keywords

Adriamycin; Cytotoxic T lymphocyte; Double grafted tumour system; Liposomes; Malignant fibrous histiocytoma

Indexed keywords

7,12 DIMETHYLBENZ[A]ANTHRACENE; ANTINEOPLASTIC AGENT; CD4 ANTIGEN; CD8 ANTIGEN; DOXORUBICIN; LIPOSOME;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CELL ACTIVATION; CELL INFILTRATION; CONTROLLED STUDY; FLUORESCENCE ACTIVATED CELL SORTER; IMMUNE RESPONSE; INTRATUMORAL DRUG ADMINISTRATION; MALE; MALIGNANT FIBROUS HISTIOCYTOMA; NONHUMAN; PRIORITY JOURNAL; RAT; SPLEEN LYMPHOCYTE; T LYMPHOCYTE;

EID: 0031417701     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (47)

1. Weiss SW and Enzinger FM: Malignant fibrous histiocytoma: an analysis of 200 cases. Cancer 41: 2250-2266, 1978.
2. Enjoji M, Hashimoto H, Tsuneyoshi M and Iwasaki H: Malignant fibrous histiocytoma: a clinicopathologic study of 130 cases. Acta Pathol Jpn 30: 724-741, 1980.
3. Kearney MM, Soule EH and Ivins JC: Malignant fibrous histiocytoma: a retrospective study of 167 cases. Cancer 45: 167-178, 1980.
4. Lee SY, Kim SS, Jeon DG and Baek GH: Malignant fibrous histiocytoma of the limbs. Int Orthop 17: 173-175, 1993.
5. Brecher ME and Franklin WA: Absence of mononuclear phagocyte antigens in malignant fibrous histiocytoma. Am J Clin Pathol 86: 344-348, 1986.
6. 3H] thymidine auto-radiography. Lab Invest 62: 635-645, 1990.
7. Roholl PJM, Kleijne J, Van Basten CDH, Van Der Putte SCJ and Van Unnik JAM: A study to analyze the origin of tumor cells in malignant fibrous histiocytomas: a multiparametric characterization. Cancer 56: 2809-2815, 1985.
8. Poste G, Bucana C, Raz A, Bugelski P, Kirsh R and Fidler I: Analysis of the fate of systemically administered liposomes and implications for their use in drug delivery. Cancer Res 42: 1412-1422, 1982.
9. Segal AW, Wills EJ, Richmond JE, Slavin G, Black CDV and Gregoriadis G: Morphological observations on the cellular and subcellular destination of intravenously administered liposomes. Br J Exp Path 55: 320-327, 1974.
10. Nishida K, Yonemura K, Abe Y and Takagi K: Antitumor effects of liposomes containing adriamycin on chemically-induced rat malignant fibrous histiocytoma. J Jpn Orthop Assoc 69: 322-331, 1995.
11. Yakushiji T, Yonemura K, Nishida K and Takagi K: Antitumor effects of adriamycin encapsulated in liposomes on chemically-induced rat malignant fibrous histiocytoma: histological aspects. J Orthp Sci: in press.
12. Gabizon A, Goren D, Fuks Z, Meshorer A and Barenholz Y: Superior therapeutic activity of liposome-associated adriamycin in a murine metastatic tumour model. Br J Cancer 51: 681-689, 1985.
13. Ichino T, Yotsuyanagi T, Mizuno I, Akamo Y, Yamamoto T, Saito T, Kurahashi S, Tanimoto N and Yura J: Antitumor effect of liposome-entrapped adriamycin administered via the portal vein. Jpn J Cancer Res 81: 1052-1056, 1990.
14. Tomazic V, Ehrke MJ and Mihich E: Modulation of the cytotoxic response against allogeneic tumor cells in culture by adriamycin. Cancer Res 40: 2748-2755, 1980.
15. Tomazic V, Ehrke MJ and Mihich E: Augmentation of the development of immune responses of mice against allogeneic tumor cells after adriamycin treatment. Cancer Res 41: 3370-3376, 1981.
16. Ehrke MJ, Ryoyama K and Cohen SA: Cellular basis for adriamycin-induced augmentation of cell-mediated cytotoxicity in culture. Cancer Res 44: 2497-2504, 1984.
17. Ehrke MJ, Maccubbin D, Ryoyama K, Cohen SA and Mihich E: Correlation between adriamycin-induced augmentation of interleukin 2 production and of cell-mediated cytotoxicity in mice. Cancer Res 46: 54-60, 1986.
18. Mace K, Mayhew E, Mihich E and Ehrke MJ: Alterations in murine host defense functions by adriamycin or liposome-encapsulated adriamycin. Cancer Res 48: 130-136, 1988.
19. Sakamoto K: Malignant fibrous histiocytoma induced by intra-articular injection of 9,10-dimethyl-1,2-benzanthracene in the rat. Pathological and enzyme histochemical studies. Cancer 57: 2312-2322, 1986.
20. Ebina T, Kohya H, Yamaguchi T and Ishida N: Antimetastatic effect of bioligical response modifiers in the "double grafted tumor system". Jpn J Cancer Res 77: 1034-1042, 1986.
21. Ebina T and Murata K: Antitumor effect of PSK at a distant site: inductions of interleukin-8-like factor and macrophage chemotactic factor in murine tumor. Jpn J Cancer Res 81: 1307-1313, 1990.
22. Ebina T and Murata K: Antitumor effector mechanism of interleukin-1β at a distant site in the double grafted tumor system. Jpn J Cancer Res 82: 1292-1298, 1991.
23. Attia MAM and Weiss DW: Immunology of spontaneous mammary carcinomas in mice. V. Acquired tumor resistance and enhancement in strain A mice infected with mammary tumor virus. Cancer Res 26: 1787-1800, 1966.
24. Heuff G, Van Der Ende MB, Boutkan H, Prevoo W, Bayon LG, Fleuren GJ, Beelen RHJ, Meijer S and Dijkstra CD: Macrophage populations in different stages of induced hepatic metastases in rats: an immunohistochemical analysis. Scand J Immunol 38: 10-16, 1993.
25. Yamashiro S, Takeya M, Nishi T, Kuratsu J, Yoshimura T, Ushio Y and Takahashi K: Tumor-derived monocyte chemoattractant protein-1 induces intratumoral infiltration of monocyte-derived macrophage subpopulation in transplanted rat tumors. Am J Pathol 145: 856-867, 1994.
26. Brideau RJ, Carter PB, McMaster WR, Mason DW and Williams AF: Two subsets of rat T lymphocytes defined with monoclonal antibodies. Eur J Immunol 10: 609-615, 1980.
27. Thomas ML and Green JR: Molecular nature of the W3/25 and MRC OX-8 marker antigens for rat T lymphocytes: comparisons with mouse and human antigens. Eur J Immunol 13: 855-858, 1983.
28. Severson CD, Burg DL, Lafrenz DE and Feldbush TL: An alternative method of panning for rat B lymphocytes. Immunol Lett 15: 291-295, 1987.
29. Bevan DJ and Chisholm PM: Co-expression of CD4 and CD8 molecules and de novo expression of MHC class II antigens on activated rat T cells. Immunol 59: 621-625, 1986.
30. Julius MH, Simpson E and Herzenberg LA: A rapid method for the isolation of functional thymus-derived murine lymphocytes. Eur J Immunol 3: 645-649, 1973.
31. Jefferies WA, Green JR and Williams AF: Authentic T helper CD4 (W3/25) antigen on rat peritoneal macrophages. J Exp Med 162: 117-127, 1985.
32. Sasaki DT, Dumas SE and Engleman EG: Discrimination of viable and non-viable cells using propidium iodide in two color immunofluorescence. Cytometry 8: 413-420, 1987.
33. Winn HJ: Immune mechanisms in homotransplantation. II. Quantitative assay of the immunologic activity of lymphoid cells stimulated by tumor homografts. J Immunol 86: 228-239, 1961.
34. Robins RA, Flannery GR and Baldwin RW: Tumour-derived lymphoid cells prevent tumour growth in Winn assays. Br J Cancer 40: 946-949, 1979.
35. Cantrell DA, Robins RA, Brooks CG and Baldwin RW: Phenotype of rat natural killer cells defined by monoclonal antibodies marking rat lymphocyte subsets. Immunol 45: 97-103, 1982.
36. Schuurman HJ, Bell EB, Gärtner K, Hedrich HJ, Hansen AK, De Vrey BCK/P, Leyten R, Maeder SJ, Moutier R, Mohnle U, Pass D, Vankerkom J, Boot R, Broekhuizen R, Dormans J, Van Herck H, Hermans PGC, Hoekman J, Van Der Logt J, Van Wijk M, Vos JG, Van Zutphen LFM: Comparative evaluation of the immune status of congenitally athymic and euthymic rat strains bred and maintained at different institutes: 2. Athymic rats. J Exp Anim Sci 35: 33-48, 1992.
37. Cook JL, Iklé DN and Routes BA: Natural killer cell ontogeny in the athymic rat: relationship between functional maturation and acquired resistance to E1A oncogene-expressing sarcoma cells. J Immunol 155: 5512-5518, 1995.
38. Moore K and Moore M: Systemic and in-situ natural killer activity in tumour-bearing rats. Br J Cancer 39: 636-647, 1979.
39. + effector T cells temporarily causes the destruction of already disseminated tumor cells. J Immunol 136: 1510-1515, 1986.
40. Nomi S, Naito K, Kahan BD and Pellis NR: Effects of concomitant and sinecomitant immunity on postsurgical metastasis in mice. Cancer Res 46: 6111-6115, 1986.
41. Belldegrun A, Kasid A, Uppenkamp M, Topalian SL and Rosenberg SA: Human tumor infiltrating lymphocytes: analysis of lymphokine mRNA expression and relevance to cancer immunotherapy. J Immunol 142: 4520-4526, 1989.
42. Greenberg PD and Cheever MA: Effector mechanisms operative in adoptive therapy of tumor-bearing animals: implications for the use of interleukin-2. J Biol Resp Modif 3: 455-461, 1984.
43. Fernandez-Cruz E, Woda BA and Feldman JD: Elimination of syngeneic sarcomas in rats by a subset of T lymphocytes. J Exp Med 152: 823-841, 1980.
44. Fernandez-Cruz E, Gilman SC and Feldman JD: Immunotherapy of a chemically-induced sarcoma in rats: characterization of the effector T cell subset and nature of suppression. J Immunol 128: 1112-1117, 1982.
45. Haskill JS: Adriamycin-activated macrophages as tumor growth inhibitors. Cancer Res 41: 3852-3856, 1981.
46. Martin F, Caignard A, Olsson O, Jeannin JF and Leclerc A: Tumoricidal effect of macrophages exposed to adriamycin in vivo or in vitro. Cancer Res 42: 3851-3857, 1982.
47. Allen TM, Hansen CB and Guo LSS: Subcutaneous administration of liposomes: a comparison with the intravenous and intraperitoneal routes of injection. Biochim Biophys Acta 1150: 9-16, 1993.